This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Oct 14;385(16):1445-1447.

doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9.

The Drug-Dosing Conundrum in Oncology - When Less Is More

Mirat Shah¹, Atiqur Rahman¹, Marc R Theoret¹, Richard Pazdur¹

Affiliations

Affiliation

¹ From the Office of Oncologic Diseases (M.S.) and the Division of Cancer Pharmacology II, Office of Clinical Pharmacology (A.R.), Center for Drug Evaluation and Research, and the Oncology Center of Excellence (M.R.T., R.P.), Food and Drug Administration, Silver Spring, MD.

PMID: 34623789
DOI: 10.1056/NEJMp2109826

The Drug-Dosing Conundrum in Oncology - When Less Is More

Mirat Shah et al. N Engl J Med. 2021.

. 2021 Oct 14;385(16):1445-1447.

doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9.

Authors

Mirat Shah¹, Atiqur Rahman¹, Marc R Theoret¹, Richard Pazdur¹

Affiliation

¹ From the Office of Oncologic Diseases (M.S.) and the Division of Cancer Pharmacology II, Office of Clinical Pharmacology (A.R.), Center for Drug Evaluation and Research, and the Oncology Center of Excellence (M.R.T., R.P.), Food and Drug Administration, Silver Spring, MD.

PMID: 34623789
DOI: 10.1056/NEJMp2109826

No abstract available

PubMed Disclaimer

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon